MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea
MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-01
MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-generation injectable drug for knee osteoarthritis, SMUP-IA-01
MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association
MEDIPOST completes the expansion of its GMP facilities for CARTISTEM, a stem cell therapy, and SMUP-IA-01, an injectable knee osteoarthritis treatment
MEDIPOST’s phase 1 clinical trial results for its injectable drug for knee osteoarthritis in Korea show improvements in safety and clinical symptoms
MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia
MEDIPOST completes the phase 1 clinical trial of its injectable drug for knee osteoarthritis, SMUP-IA-01
